LGALS3BP and Hepatic fibrosis: In our study, subjects with higher M2BP levels would have enhanced liver inflammation, but the anti-inflammatory effects of M2BP would be not sufficient to suppress inflammation, which led to further liver fibrosis progression during the 7-year study.